Drug Trial Radar · NCT05568095
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,040
Actual
Start
Nov 21, 2022
Primary completion
Aug 28, 2026
Study completion Aug 28, 2026
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences; Taiho Pharmaceutical Co., Ltd.
- First posted
- Oct 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Conditions
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
DomvanalimabDrug
Intravenous (IV) Aqueous Solution
ZimberelimabDrug
IV Aqueous Solution
CapecitabineDrug
Oral Tablets
FluorouracilDrug
IV Aqueous Solution
LeucovorinDrug
IV Aqueous Solution
OxaliplatinDrug
IV Aqueous Solution
NivolumabDrug
IV Aqueous Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: From date of randomization until date of death from any cause (Approximately 15 months)]
Locations
168 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Santa Monica, California
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Fort Myers, Florida
Research Site
St. Petersburg, Florida
Research Site
Tallahassee, Florida
Research Site
Louisville, Kentucky
Research Site
Louisville, Kentucky
Research Site
New Orleans, Louisiana
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Saint Louis Park, Minnesota
Research Site
Mineola, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Cleveland, Ohio
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Mayfield Heights, Ohio
Research Site
Portland, Oregon
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Seattle, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
La Rioja, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Clayton, Australia
Research Site
Murdoch, Australia
Research Site
Barretos, Brazil
Research Site
Ijuí, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.